Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2014, Article ID 564308, 3 pages
http://dx.doi.org/10.1155/2014/564308
Research Article

Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients

1Department of Surgery, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran
2International Azad University of Kish, Kish, Iran
3Students’ Research Committee, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran

Received 20 May 2014; Accepted 24 October 2014; Published 12 November 2014

Academic Editor: Vladimir F. Semiglazov

Copyright © 2014 Seyed Abbas Mirmalek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Pietras, J. Arboleda, D. M. Reese et al., “HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells,” Oncogene, vol. 10, no. 12, pp. 2435–2446, 1995. View at Google Scholar · View at Scopus
  2. K. B. Horwitz and W. L. McGuire, “Specific progesterone receptors in human breast cancer,” Steroids, vol. 25, no. 4, pp. 497–505, 1975. View at Publisher · View at Google Scholar · View at Scopus
  3. W. L. McGuire, M. De La Garza, and G. C. Chamness, “Evaluation of estrogen receptor assays in human breast cancer tissue,” Cancer Research, vol. 37, no. 3, pp. 637–639, 1977. View at Google Scholar · View at Scopus
  4. R. Hahnel, T. Woodings, and A. B. Vivian, “Prognostic value of estrogen receptors in primary breast cancer,” Cancer, vol. 44, no. 2, pp. 671–675, 1979. View at Publisher · View at Google Scholar · View at Scopus
  5. U. Bohn, J. Aguiar, C. Bilbao et al., “Prognostic value of the quantitative measurement of the oncoprotein P185 Her-2/neu in a group of patients with breast cancer and positive node involvement,” International Journal of Cancer, vol. 101, no. 6, pp. 539–544, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Dimas, M. Frangos-Plemenos, E. Kouskouni, and A. Kondis-Pafitis, “Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker,” International Journal of Gynecological Cancer, vol. 12, no. 1, pp. 74–79, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. H. K. W. Koeppen, B. D. Wright, A. D. Burt et al., “Overexpression of HER2/neu in solid tumours: an immunohistochemical survey,” Histopathology, vol. 38, no. 2, pp. 96–104, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Tanner, D. Gancberg, B. A. D. Leo et al., “Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples,” The American Journal of Pathology, vol. 157, no. 5, pp. 1467–1472, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. B. M. Ryan, G. E. Konecny, S. Kahlert et al., “Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1,” Annals of Oncology, vol. 17, no. 4, pp. 597–604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Ronckers, C. A. Erdmann, and C. E. Land, “Radiation and breast cancer: a review of current evidence,” Breast Cancer Research, vol. 7, no. 1, pp. 21–32, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Kaptain, L. K. Tan, and B. Chen, “Her-2/neu and breast cancer,” Diagnostic Molecular Pathology, vol. 10, no. 3, pp. 139–152, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Hatanaka, K. Hashizume, Y. Kamihara et al., “Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest in breast carcinoma by image analysis,” Pathology International, vol. 51, no. 1, pp. 33–36, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. M. A. Olayioye, “Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members,” Breast Cancer Research, vol. 3, no. 6, pp. 385–389, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. A.-M. Martin and B. L. Weber, “Genetic and hormonal risk factors in breast cancer,” Journal of the National Cancer Institute, vol. 92, no. 14, pp. 1126–1135, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. R. M. Elledge and D. C. Allred, “The p53 tumor suppressor gene in breast cancer,” Breast Cancer Research and Treatment, vol. 32, no. 1, pp. 39–47, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. D. J. Slamon, W. Godolphin, L. A. Jones et al., “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer,” Science, vol. 244, no. 4905, pp. 707–712, 1989. View at Publisher · View at Google Scholar · View at Scopus
  17. C. W. Elston and I. O. Ellis, “Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up,” Histopathology, vol. 19, no. 5, pp. 403–410, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt, “Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 1983–1987, 1999. View at Google Scholar · View at Scopus
  19. D. M. Barnes, E. A. Dublin, C. J. Fisher, D. A. Levison, and R. R. Millis, “Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?” Human Pathology, vol. 24, no. 5, pp. 469–476, 1993. View at Publisher · View at Google Scholar · View at Scopus